Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study
Cephalalgia · 2026
DOI: 10.1177/03331024261478621 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, 2026. Verfasst von Hui Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Migraine Disorders, Analgesics, Severity of Illness Index. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Municipal Science and Health Joint Medical Research Project.
Abstract (Originalsprache)
Aim
To determine whether a two-variable scorecard combining monthly acute medication days and the six-item Migraine Treatment Optimization Questionnaire can identify high multidimensional migraine burden, defined operationally as a four-domain composite (monthly migraine days, acute medication days, pain intensity, and disability) score ≥50 (range 0–100), with sufficient discrimination and clinical utility for bedside triage.
Methods
We performed a cross-sectional analysis of baseline data from a multicenter, prospective, real-world migraine registry in China (enrolment January 2024 – December 2025). Adults with migraine and complete data for the four-domain composite and the six-item Migraine Treatment Optimization Questionnaire were included (total sample, 1161; derivation cohort, 344; external validation cohort, 817). A two-predictor logistic regression model was developed at the coordinating center and validated at the remaining centers. Bootstrap-adjusted discrimination and calibration were assessed. A categorical version of the model was converted into an integer scorecard (0–11 points) with decision-curve-derived triage zones.
Results
The area under the receiver operating characteristic curve was 0.899 (95% confidence interval 0.863–0.935) in derivation and 0.866 (0.837–0.895) in external validation. Calibration in the validation cohort showed systematic overestimation (expected-to-observed ratio 1.85); after intercept recalibration, the Brier score decreased from 0.14 to 0.11. Decision curve analysis showed net benefit across threshold probabilities 0.10–0.50. In validation, the Green zone (score ≤2) included 313 participants (38.3%) with a negative predictive value of 0.98; the Yellow zone (score 3–4) included 180 (22.0%); and the Red zone (score ≥5) included 324 (39.7%) with a positive predictive value of 0.45. Monthly acute medication days accounted for most of the discriminative performance; the treatment-optimization component provided additional stratification, particularly in the intermediate medication-use range (4–14 days/month).
Conclusion
The Migraine Analgesic Usage Index offers a concise, externally validated triage aid for identifying high multidimensional migraine burden as defined by the four-domain composite. It may help prioritize comprehensive assessment but does not replace clinical evaluation. Prospective studies should test whether index-guided triage improves decision quality and patient outcomes.
Trial registration
Chinese Clinical Trial Registry, https://www.chictr.org.cn/ , ChiCTR2400083678.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Phase I Clinical Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Neurology, Chongqing People's Hospital, Chongqing, China.
- Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- Department of Geriatric Medicine and Neurology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
- West China-PUMC C.C. Chen Institute of Health, Sichuan University, Chengdu, China.
ORCID-Profile: Hui Li, Linyi Che, Peiwei Hong, Liang Dong, Jiying Zhou
Förderung
- Chongqing Municipal Science and Health Joint Medical Research Project
Zitieren
APA
Li, H., Xu, X., Che, L., Fan, X., Tan, G., Ma, J., Pan, Q., Hong, P., Zhong, C., Li, J., Chen, X., Dong, L., & Zhou, J. (2026). Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study. Cephalalgia. https://doi.org/10.1177/03331024261478621
Vancouver
Li H, Xu X, Che L, Fan X, Tan G, Ma J, et al. Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study. Cephalalgia. 2026. doi:10.1177/03331024261478621
BibTeX
@article{Li2026,
author = {Li, Hui and Xu, Xiaonuo and Che, Linyi and Fan, Xiaoping and Tan, Ge and Ma, Jingxi and Pan, Qi and Hong, Peiwei and Zhong, Chengqing and Li, Jiao and Chen, Xiaorong and Dong, Liang and Zhou, Jiying},
title = {Development and external validation of a migraine analgesic usage (MAU) index for identifying high-severity migraine: A multi-center study},
journal = {Cephalalgia},
year = {2026},
doi = {10.1177/03331024261478621}
}
EUVIMED